(Q33378309)

English

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

Christian Geisler

3

object named as

Christian Geisler

0 references

5

object named as

Harald Holte

1 reference

Europe PubMed Central

26 July 2017

object named as

Eva Kimby

1

1 reference

ORCID Public Data File 2021

4

object named as

Hans Hagberg

1 reference

Europe PubMed Central

26 July 2017

author name string

Jesper Jurlander

2

1 reference

Europe PubMed Central

26 July 2017

Christian Geisler

3

1 reference

Europe PubMed Central

26 July 2017

Tuula Lehtinen

6

1 reference

Europe PubMed Central

26 July 2017

Björn Ostenstad

7

1 reference

Europe PubMed Central

26 July 2017

Mads Hansen

8

1 reference

Europe PubMed Central

26 July 2017

Anders Osterborg

9

1 reference

Europe PubMed Central

26 July 2017

Ola Lindén

10

1 reference

Europe PubMed Central

26 July 2017

Christer Sundström

11

1 reference

Europe PubMed Central

26 July 2017

Nordic Lymphoma Group

12

1 reference

Europe PubMed Central

26 July 2017

publication date

1 January 2008

1 reference

Europe PubMed Central

26 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

26 July 2017

49

1 reference

Europe PubMed Central

26 July 2017

1

1 reference

Europe PubMed Central

26 July 2017

102-112

1 reference

Europe PubMed Central

26 July 2017

Treatment strategies in follicular lymphomas: current status and future perspectives

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

From the bench to the bedside: ways to improve rituximab efficacy.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Detection of immunoglobulin gene rearrangement in B lymphoid malignancies by polymerase chain reaction gene amplification.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Tolerability and safety of rituximab (MabThera).

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190701704647

21 January 2018

Identifiers

10.1080/10428190701704647

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33378309&oldid=2067072595"